Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

Descripción completa

Detalles Bibliográficos

Autores principales:	Hannah M. Garcia Garrido, Albert Vollaard, Geert R. D’Haens, Phyllis I. Spuls, Frederike J. Bemelman, Michael W. Tanck, Godelieve J. de Bree, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-05-01
Colección:	Vaccines
Materias:	pneumococcal vaccination immunocompromised host transplant recipient autoimmune disease vaccine immunogenicity
Acceso en línea:	https://www.mdpi.com/2076-393X/10/5/795
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!